@entity1239 reduces antipsychotic-induced XXXX in @entity35 .

@entity1 @entity935 @entity1239 @entity910 @entity914 @entity161 @entity8364 @entity1767 @entity35 @entity717 @entity934
Antipsychotics are an important class of drugs for the management of @entity161 and other @entity914 . They act by blocking @entity935 receptors; however, because these receptors are present throughout the brain, prolonged antipsychotic use also leads to serious side effects. These include @entity910 , repetitive @entity910 of the face and limbs for which there is little treatment. In this study, we investigated whether @entity1239 administration could reduce @entity910 because @entity1239 attenuates other drug-induced @entity910 . We used a well established model of @entity910 in which @entity35 injected with the commonly used antipsychotic @entity1767 develop @entity717 ( @entity717 ) that resemble @entity1 @entity910 . @entity35 were first administered @entity1239 (minipump; 2 mg/kg per day). Two weeks later, they were given @entity1767 (1 mg/kg s.c.) once daily. @entity1239 treatment reduced @entity1767 -induced @entity717 by    20% after 5 weeks, with a significant    60% decline after 13 weeks. There was no worsening of @entity1767 -induced @entity8364 . To understand the molecular basis for this improvement, we measured the striatal @entity935 transporter and nicotinic @entity934 receptors (nAChRs). Both @entity1767 and @entity1239 treatment decreased the transporter and a6b2* nAChRs (the asterisk indicates the possible presence of other nicotinic subunits in the receptor complex) when given alone, with no further decline with combined drug treatment. By contrast, @entity1239 alone increased, while @entity1767 reduced a4b2* nAChRs in both vehicle and @entity1767 -treated @entity35 . These data suggest that molecular mechanisms other than those directly linked to the transporter and nAChRs underlie the @entity1239 -mediated improvement in @entity1767 -induced @entity717 in @entity35 . The present results are the first to suggest that @entity1239 may be useful for improving the @entity910 associated with antipsychotic use.
